Humanigen

About:

Humanigen is a biopharmaceutical company that focuses on developing human antibody therapeutics.

Website: http://www.humanigen.com

Twitter/X: humanigen

Top Investors: Hercules Capital, Fidelity, Sofinnova Investments, Mitsubishi UFJ Capital, 5AM Ventures

Description:

Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.

Total Funding Amount:

$357M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Burlingame, California, United States

Founded Date:

2001-01-01

Contact Email:

questions(AT)humanigen.com

Founders:

Jeng Her, Robert Balint

Number of Employees:

11-50

Last Funding Date:

2021-03-31

IPO Status:

Public

© 2025 bioDAO.ai